GlassScriptPhysician profile
Lacy J Wilson
NPI 1568111482
$2,088.45
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $506 · 2023: $1,047 · 2024: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.69 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.00 | 2022-2024 | |
| Novo Nordisk INC | $308.38 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $159.69 | 2023-2024 | Aptiom, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $132.58 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $120.56 | 2023-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| Lilly USA, LLC | $115.45 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $107.81 | 2022-2024 | |
| Ibsa Pharma INC. | $90.64 | 2022-2024 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $75.52 | 2023-2024 | Breztri, Airsupra |
| Amgen INC. | $65.29 | 2022 | |
| Dexcom, INC. | $55.40 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $52.31 | 2022-2024 | Veozah |
| Indivior INC. | $42.43 | 2023-2024 | Sublocade |
| Exact Sciences Corporation | $39.24 | 2023-2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $32.26 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.74 | 2022-2023 | Trintellix |
| Abbott Laboratories | $29.97 | 2024 | Freestyle Insulinx |
| Lucid Diagnostics INC. | $28.13 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.95 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $24.79 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.49 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $19.15 | 2023 | |
| Sanofi Pasteur INC. | $18.51 | 2023 | |
| Glaxosmithkline, LLC. | $17.36 | 2022 | |
| Evoke Pharma, INC. | $17.21 | 2023 | Gimoti |
| Lundbeck LLC | $16.08 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $15.82 | 2024 | Dificid |
| Janssen Pharmaceuticals, INC | $13.93 | 2023 | Xarelto |
| Ultragenyx Pharmaceutical INC. | $12.63 | 2022 | |
| Urovant Sciences INC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.